Novartis Cyclosporine Sales Advance 12% To $637 Mil. At Half-Year Mark
Executive Summary
Despite the advent of generic competition in the U.S., sales of Novartis' Sandimmun/Neoral cyclosporine franchise advanced 12% in local currencies in the first six months of 1999.
You may also be interested in...
FDA Elimination Of Neoral "Microemulsion" Designation Disputed By Novartis
FDA's elimination of "microemulsion" dosage forms is unlawful, Novartis contended in a Feb. 11 lawsuit challenging FDA's approval of SangStat's generic version of Neoral (cyclosporine).
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials